Biodesix Q3FY26 Results: Revenue misses estimates, stock falls 29%
Biodesix Inc reported Q3FY26 revenue of $24.0M, missing estimates of $27.44M. Shares fell 29.44% after-hours. Full-year guidance was reduced to $101M-$103M from $108M-$114M. Revenue growth was 10% YoY, but test volume growth was offset by lower revenue per test. Gross margin remained at 81%, and net loss improved 8% YoY to $8.0M.
How this was made
The 30-second read
Why it matters
The earnings miss and guidance reduction drove a 29% share plunge, indicating immediate sell pressure.
Market read
First‑report earnings and guidance cut for a small‑cap biotech, causing a sharp price move.
What to watch
Strong gross margin and 16% EBITDA loss improvement suggest cost controls are taking effect.
Background
Biodesix reported Q3 FY26 results with revenue below estimates and cut full‑year guidance.
Market effects
Diagnostic testing sector may see heightened scrutiny on mix shift to lower‑priced tests.
US biotech market could experience broader risk‑off sentiment.
Limited to investors focused on small‑cap US biotech.
Counterpoint
Volume growth remains strong; mix shift to lower‑cost tests could improve margins over time.
Key entities
- companyBiodesix Inc
US‑listed diagnostics firm (ticker BDX).
